Differentiating hepatocellular carcinoma from hepatitis C using metabolite profiling.
Differentiating hepatocellular carcinoma from hepatitis C using metabolite profiling.
复制标题
DOI：
10.3390/metabo2040701
复制
发表时间：
2012-10-10
期刊：
影响因子：
4.1
通讯作者：
Raftery D
中科院分区：
文献类型：
--
作者：
Wei S;Suryani Y;Gowda GA;Skill N;Maluccio M;Raftery D
肝细胞癌（HCC）占全球大多数肝癌病例。丙型肝炎病毒（HCV）的收缩被认为是肝癌的主要危险因素。为了确定癌症的风险，通过1H核磁共振光谱法对来自HCC（n=40）和HCV（n=22）患者的血清样品进行代谢谱分析。多变量统计分析显示两个患者队列的明显分离，表明基于来自脂质和其他个体代谢物的信号，HCC和HCV患者组之间存在明显的代谢差异。单因素分析显示，三种代谢产物（胆碱，缬氨酸和肌酐）在HCC中发生显著变化。基于这三种代谢物的PLS-DA模型显示灵敏度为80%，特异性为71%，受试者工作曲线下面积为0.83，优于临床标志物甲胎蛋白（AFP）。使用蒙特-卡罗交叉验证（MCCV）检验模型的稳健性。这项研究表明，代谢产物谱分析可以为HCV患者的HCC筛查提供一种替代方法，其中许多人具有患肝癌的高风险。
Hepatocellular carcinoma (HCC) accounts for most liver cancer cases worldwide. Contraction of the hepatitis C virus (HCV) is considered a major risk factor for liver cancer. In order to identify the risk of cancer, metabolic profiling of serum samples from patients with HCC (n=40) and HCV (n=22) was performed by 1H nuclear magnetic resonance spectroscopy. Multivariate statistical analysis showed a distinct separation of the two patient cohorts, indicating a distinct metabolic difference between HCC and HCV patient groups based on signals from lipids and other individual metabolites. Univariate analysis showed that three metabolites (choline, valine and creatinine) were significantly altered in HCC. A PLS-DA model based on these three metabolites showed a sensitivity of 80%, specificity of 71% and an area under the receiver operating curve of 0.83, outperforming the clinical marker alpha-fetoprotein (AFP). The robustness of the model was tested using Monte-Carlo cross validation (MCCV). This study showed that metabolite profiling could provide an alternative approach for HCC screening in HCV patients, many of whom have high risk for developing liver cancer.